Ipamorelin Side Effects

What are the reported side effects of ipamorelin?

The published record describes ipamorelin as a selective GH secretagogue with minimal cortisol and prolactin effect in the study model, not a compound with a defined human side-effect profile.

Ipamorelin was characterized by Raun and colleagues as a pentapeptide that releases growth hormone. The notable finding was selectivity: in the study, ipamorelin stimulated GH release without the parallel rise in ACTH, cortisol, and prolactin seen with some comparator secretagogues (Raun et al., 1998). That selectivity is the single most-cited point about the compound, and it is a study finding in a preclinical model, not a safety guarantee for any person.

Because the depth of published human research on ipamorelin is limited, statements about how people tolerate it should be read as extrapolation from mechanism and from the broader GH secretagogue class, not as established clinical fact.

Does ipamorelin raise cortisol or prolactin?

In the characterization study, ipamorelin released GH with minimal effect on cortisol and prolactin, which is why it is described as selective (Raun et al., 1998).

This is the finding the compound is known for. Earlier GH secretagogues and some releasing agents also stimulated the hypothalamic-pituitary-adrenal axis, raising ACTH and cortisol alongside GH. Raun and colleagues reported that ipamorelin did not produce that same non-selective response in their model, releasing GH while leaving cortisol and prolactin largely unchanged (Raun et al., 1998). The word "minimal" is important: it reflects what the study measured, not a promise of zero effect in any individual.

Can GH secretagogues affect blood sugar?

Yes, research on the drug class reports effects on glucose handling, so this is a documented consideration for GH secretagogues broadly.

Ipamorelin itself has limited published human metabolic data. The clearest human signal in the class comes from MK-677 (ibutamoren), an orally active GH secretagogue. In a study by Nass and colleagues, MK-677 raised fasting glucose and lowered insulin sensitivity over the treatment period (Nass et al., 2008). Growth hormone has counter-regulatory effects on insulin, so any agent that sustains higher GH or IGF-1 output could plausibly touch glucose metabolism. This is class-level context, not a direct measurement of ipamorelin, and it is one reason glucose-related questions belong with a clinician.

For comparison, another GH-axis peptide, CJC-1295, was shown to sustain raised GH and IGF-1 levels in humans (Teichman et al., 2006), which underscores that duration and magnitude of GH elevation differ across compounds in this space.

How does ipamorelin compare to other GH secretagogues on tolerability signals?

Ipamorelin is distinguished in the literature by its selective GH release, while other class members show broader hormonal or metabolic signals in their respective studies.

This grid summarizes what each cited study reported for its own compound. The studies used different models, designs, and endpoints, so the table is a reference map, not a head-to-head safety ranking.

What dosing has research reported for ipamorelin?

Published human dose-response data specific to ipamorelin is limited, so this page does not state a use dose, and any personal protocol is a clinician's decision.

The foundational work by Raun and colleagues was a pharmacological characterization establishing selectivity and GH-releasing potency in a preclinical setting, not a human dose-finding trial with a defined tolerated range (Raun et al., 1998). Because that dose-response evidence in humans is not established in the sources here, no research-reported human dosing range is presented. Framing what to take, when, or how would go beyond what the literature supports and beyond what this page will do. Those questions route to a qualified clinician.

Is ipamorelin proven safe in humans?

No, the published record does not establish a defined human safety profile for ipamorelin; the primary characterization is preclinical (Raun et al., 1998).

Human safety data on ipamorelin specifically is limited. What the literature offers is a mechanism (selective GH secretagogue), a selectivity finding (minimal cortisol and prolactin effect in the model), and class-level context from related agents (Raun et al., 1998; Nass et al., 2008). None of that constitutes a completed human safety demonstration. Descriptions here are educational summaries of study findings, not medical claims, and not a guarantee of any outcome or tolerability for any person.